Correlation Between ABVC Biopharma and Catalyst Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both ABVC Biopharma and Catalyst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ABVC Biopharma and Catalyst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ABVC Biopharma and Catalyst Pharmaceuticals, you can compare the effects of market volatilities on ABVC Biopharma and Catalyst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ABVC Biopharma with a short position of Catalyst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of ABVC Biopharma and Catalyst Pharmaceuticals.

Diversification Opportunities for ABVC Biopharma and Catalyst Pharmaceuticals

-0.43

Correlation Coefficient

ABVC Biopharma  Catalyst Pharmaceuticals

Very good diversification

The 3 months correlation between ABVC and Catalyst is -0.43. Overlapping area represents the amount of risk that can be diversified away by holding ABVC Biopharma and Catalyst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Catalyst Pharmaceuticals and ABVC Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ABVC Biopharma are associated (or correlated) with Catalyst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Catalyst Pharmaceuticals has no effect on the direction of ABVC Biopharma i.e., ABVC Biopharma and Catalyst Pharmaceuticals go up and down completely randomly.

Pair Corralation between ABVC Biopharma and Catalyst Pharmaceuticals

Given the investment horizon of 90 days ABVC Biopharma is expected to generate 3.95 times more return on investment than Catalyst Pharmaceuticals. However, ABVC Biopharma is 3.95 times more volatile than Catalyst Pharmaceuticals. It trades about 0.06 of its potential returns per unit of risk. Catalyst Pharmaceuticals is currently generating about -0.08 per unit of risk. If you would invest  137.00  in ABVC Biopharma on January 30, 2024 and sell it today you would earn a total of  5.00  from holding ABVC Biopharma or generate 3.65% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	95.45%
Values	Daily Returns

ABVC Biopharma  vs.  Catalyst Pharmaceuticals

ABVC Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days ABVC Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, ABVC Biopharma is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders.

Catalyst Pharmaceuticals

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Catalyst Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Catalyst Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with ABVC Biopharma and Catalyst Pharmaceuticals

The main advantage of trading using opposite ABVC Biopharma and Catalyst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ABVC Biopharma position performs unexpectedly, Catalyst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will offset losses from the drop in Catalyst Pharmaceuticals' long position.

The idea behind ABVC Biopharma and Catalyst Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.